Imagion Biosystems has released “Notice Pursuant to Section 708A(5)(e) of the Corporations Act.”
Read the notice.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance